International medical tourists face significant legal and clinical barriers when enrolling in lung cancer clinical trials in Italy. While major research centers like San Raffaele in Milan operate as global oncology hubs, most trials require Italian residency or an EU health card. Non-EU patients must navigate strict AIFA regulations and complex medical visa requirements.
- Residency requirement: Most Italian oncology trials prioritize Italian residents or EU health card holders.
- Regulatory oversight: The Italian Medicines Agency (AIFA) governs trials under strict EU Regulation 536/2014.
- Medical visa: Non-EU nationals require a Schengen Medical Visa with a formal hospital invitation.
- Language barrier: Informed consent processes often require proficiency in Italian for valid symptom reporting.
Bookimed Expert Insight: While Italy is a leader in thoracic research, its trial system is not traditionally designed for medical tourists. San Raffaele in Milan performs over 52,000 operations annually and holds prestigious IRCCS accreditation. However, patients without EU citizenship often find easier trial access in Germany or Switzerland. These neighboring countries frequently provide more robust infrastructure for international trial participants and English-speaking coordinators.
Patient Consensus: Patients note that paperwork for non-EU citizens can be nearly impossible to complete for clinical trials. Many suggest checking eligibility directly with trial sponsors before traveling to Milan or Rome to avoid rejection.